PFM
RNAM

Privium Fund Management’s Avidity Biosciences RNAM Stock Holding History

Privium Fund Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-53,000
Closed -$2.31M – 62
2025
Q3 		$2.31M Buy
53,000
+7,000
+15% +$283K 0.42% 27
2025
Q2 		$1.31M Buy
46,000
+11,500
+33% +$343K 0.28% 27
2025
Q1 		$1.02M Buy
34,500
+2,600
+8% +$81K 0.27% 32
2024
Q4 		$928K Buy
31,900
+6,300
+25% +$263K 0.21% 34
2024
Q3 		$1.18M Buy
25,600
+3,358
+15% +$146K 0.29% 32
2024
Q2 		$863K Buy
22,242
+14,200
+177% +$407K 0.22% 47
2024
Q1 		$205K Buy
+8,042
New +$126K 0.05% 83

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Privium Fund Management's RNAM Position: Q4 2025 in Review

Privium Fund Management sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 53,000 shares — an estimated $2.31M sold.

Privium Fund Management first reported a position in RNAM in Q1 2024 and held it in 7 quarters. The position peaked at $2.31M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Privium Fund Management reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Privium Fund Management sold 53,000 Avidity Biosciences shares in Q4 2025, an estimated $2.31M.
  • Privium Fund Management first reported a position in Avidity Biosciences in Q1 2024 and held it in 7 quarters.
  • Privium Fund Management's Avidity Biosciences position peaked at $2.31M in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Privium Fund Management's 13F filing for Q4 2025, filed 3 Feb 2026.